Literature DB >> 7976510

Profile of ligand specificity of the vitamin D binding protein for 1 alpha,25-dihydroxyvitamin D3 and its analogs.

J E Bishop1, E D Collins, W H Okamura, A W Norman.   

Abstract

The profile of structural preference for the ligand binding domain of the human vitamin D binding protein (DBP) was determined by steroid competition assay of 71 analogs of 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2D3]. The following categories of structural modification were evaluated [values represent fold change; R = reduction, I = increase in binding to the DBP from the reference 1 alpha, 25(OH)2D3]: (1) deletion in the A ring of the 1 alpha-hydroxyl-(20-1600I); (2) conversion of the triene system to the previtamin form (6-40R); (3) addition of substituents to carbon 11 of the C ring (4-14R); (4) inversion of the C/D ring junction (8-20R); (5) unsaturation of the D ring (16-ene; 4-140R); (6) replacement of hydrogen with deuterium atoms (no effect); alteration of the side chain by (7) adding or deleting carbon atoms (5-12R); (8) addition of fluorines (0.2-10R); (9) presence of unsaturation (22-ene, 0-5R; 23-ene, 3R-10I; 23-yne, 5-20R); (10) addition of hydroxyls (2-100R); and (11) addition of an aromatic ring (0-20I). Thus the DBP ligand binding domain could tolerate only modest changes to the structure of 1 alpha,25(OH)2D3 without a reduction in binding of the analog. The increases in binding seen in the aromatic side chain and with a triple bond at carbon-23 may be indicative of a preferred conformation of the flexible 1 alpha, 25(OH)2D3 side chain. In addition, a comparison was made of the DBP ligand binding domain with that of the human HL-60 cell 1 alpha, 25(OH)2D3 nuclear receptor. Both ligand binding domains could equivalently accommodate to the presence of (1) a side-chain cyclopropyl group, (2) 22-ene or 23-yne, (3) lengthening the side chain by two carbons, (4) presence of four to six fluorine atoms, (5) substitution of an oxygen for carbon 22, and (6) presence of a 22-[m-(dimethylhydroxymethyl)phenyl] aromatic group in the side chain. The DPB could tolerate better than the HL-60 cell receptor the presence of a 22-(p-hydroxyphenyl) aromatic group in the side chain and the absence of the 1 alpha-hydroxyl. In contrast, the HL-60 cell receptor could tolerate better than the DBP the following structural modifications: presence of a 16-ene, or 16-ene plus 23-yne unsaturation, and presence of an 11 beta-hydroxyl.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7976510     DOI: 10.1002/jbmr.5650090818

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  13 in total

Review 1.  Structure function studies: identification of vitamin D analogs for the ligand-binding domains of important proteins in the vitamin D-endocrine system.

Authors:  A W Norman; F R Silva
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

2.  Single A326G mutation converts human CYP24A1 from 25-OH-D3-24-hydroxylase into -23-hydroxylase, generating 1alpha,25-(OH)2D3-26,23-lactone.

Authors:  David E Prosser; Martin Kaufmann; Brendan O'Leary; Valarie Byford; Glenville Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-23       Impact factor: 11.205

3.  Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP).

Authors:  A Kissmeyer; I S Mathiasen; S Latini; L Binderup
Journal:  Endocrine       Date:  1995-04       Impact factor: 3.633

4.  High dietary vitamin D prevents hypocalcemia and osteomalacia in CYP27B1 knockout mice.

Authors:  Matthew J Rowling; Christy Gliniak; JoEllen Welsh; James C Fleet
Journal:  J Nutr       Date:  2007-12       Impact factor: 4.798

5.  Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease.

Authors:  Daijo Inaguma; Hiroshi Nagaya; Kazuhiro Hara; Miho Tatematsu; Hibiki Shinjo; Sachiyo Suzuki; Tomoko Mishima; Kei Kurata
Journal:  Clin Exp Nephrol       Date:  2008-01-09       Impact factor: 2.801

6.  Calcitriol imparts neuroprotection in vitro to midbrain dopaminergic neurons by upregulating GDNF expression.

Authors:  Rowan P Orme; Manminder S Bhangal; Rosemary A Fricker
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

7.  Genetic Polymorphisms in Vitamin D Metabolism and Signaling Genes and Risk of Breast Cancer: A Nested Case-Control Study.

Authors:  Tess V Clendenen; Wenzhen Ge; Karen L Koenig; Tomas Axelsson; Mengling Liu; Yelena Afanasyeva; Anne Andersson; Alan A Arslan; Yu Chen; Göran Hallmans; Per Lenner; Tomas Kirchhoff; Eva Lundin; Roy E Shore; Malin Sund; Anne Zeleniuch-Jacquotte
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

Review 8.  Role of anabolic agents in colorectal carcinogenesis: Myths and realities (Review).

Authors:  Theodore Krasanakis; Taxiarchis Konstantinos Nikolouzakis; Markos Sgantzos; Theodore Mariolis-Sapsakos; John Souglakos; Demetrios A Spandidos; Christina Tsitsimpikou; Aristidis Tsatsakis; John Tsiaoussis
Journal:  Oncol Rep       Date:  2019-10-03       Impact factor: 3.906

9.  The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

10.  Synthesis of 1alpha,25-dihydroxyvitamin D analogues featuring a S(2)-symmetric CD-ring core.

Authors:  Garrett Minne; Lieve Verlinden; Annemieke Verstuyf; Pierre J De Clercq
Journal:  Molecules       Date:  2009-02-24       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.